3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Carcinoma, Hepatocellular
19
Carcinoma, Renal Cell
13
Parkinson Disease 4, Autosomal Dominant Lewy Body
10
Endometrial Neoplasms
6
Neoplasms
4
Biliary Tract Neoplasms
4
Neuroendocrine Tumors
3
Melanoma
3
Liver Neoplasms
3
Vulvar Neoplasms
2
Uterine Cervical Neoplasms
2
Triple Negative Breast Neoplasms
2
Stomach Neoplasms
2
Pancreatic Neoplasms
2
Ovarian Neoplasms
2
Neoplasm Metastasis
2
Colorectal Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Brain Neoplasms
2
von Hippel-Lindau Disease
1
Thyroid Neoplasms
1
Thyroid Carcinoma, Anaplastic
1
Squamous Cell Carcinoma of Head and Neck
1
Small Cell Lung Carcinoma
1
Skin Neoplasms
1
Penile Neoplasms
1
Multiple Endocrine Neoplasia Type 1
1
Lung Neoplasms
1
Kidney Neoplasms
1
Hormone Receptor-Positive HER2-Negative Advanced Breast Cancer
1
Interventions
Etoposide
30
Carboplatin
29
atezolizumab
17
durvalumab
16
Cisplatin
14
Topotecan
11
Specimen Handling
9
PM 01183
9
Magnetic Resonance Spectroscopy
7
pembrolizumab
6
olaparib
5
berzosertib
4
anlotinib
4
Radiotherapy
4
Nivolumab
4
Irinotecan
4
Drug Therapy
4
tremelimumab
3
toripalimab
3
tislelizumab
3
Paclitaxel
3
Injections
3
Docetaxel
3
Biopsy
3
Bevacizumab
3
AMG 757
3
sacituzumab govitecan
2
monalizumab
2
cabozantinib
2
Temozolomide
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Small Cell Lung Carcinoma
×
lenvatinib
×
90 days
×
Clear all
NCT04938817
2026-06-01
KEYNOTE-B98
Merck Sharp & Dohme LLC
Phase 1/2
Active not recruiting
110 enrolled